Why the study?
What are the pharmacokinetic, pharmacodynamic, and clinical characteristics of macitentan for the treatment of pulmonary arterial hypertension?
What are the pharmacokinetic, pharmacodynamic, and clinical characteristics of macitentan for the treatment of pulmonary arterial hypertension?
Macitentan is a once-daily dual endothelin receptor antagonist with a favorable pharmacokinetic and safety profile that reduces morbidity and mortality in pulmonary arterial hypertension.
No takes yet. Share an insight, caveat, or question.
May support macitentan preference in PAH for dosing and outcomes; leaves open head-to-head comparisons with other ERAs.
Sidharta et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: